Pharmaceuticals & Therapeutics

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

Pharma giant Bayer partners with AI innovator Cradle, betting on generative AI to accelerate its biologics pipeline and reshape modern medicine.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

A new nationwide study reveals a massive gap in care for heart failure patients, costing lives and billions. Why are proven, cheap medications being overlooked?

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

With a major new facility planned and a dynamic market, all eyes are on Clean Harbors as it prepares to address investors at two key January events.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

A new philanthropic fund, Lupus Ventures, aims to end treatment stagnation by investing directly in the most promising biotech innovations for lupus.

In a strategic move to become a one-stop shop for medical implants, Resonetics acquires pulse generator tech, targeting the booming neuromodulation and BCI markets.

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Weight-loss drugs offer powerful results, but what happens next? New programs aim to build lasting habits, addressing the missing link for long-term success.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.